11 results about "Human prostate" patented technology

A kind of ethenyl indole and medium ring compound and its synthesis method, compound includes axial chiral ethenyl indole and nine-membered ring compound and ethenyl indole and eight-membered ring compound, structural formula is as shown in formula 3 and formula 6 respectively;Synthesis method: with formula 1 compound 3-ethynyl-2-indole methanol and formula 2 compound 2-indole ethanol / formula 5 compound 2-indole methanol as reaction raw material is added to organic solvent, additive is added, under the catalysis of catalyst and under certain temperature condition stirring reaction, TLC is tracked to complete reaction, filter, concentrate, purify and obtain.The ethenyl indole and medium ring compound synthesized in the application, through biological activity test, shows that the two types of derivatives have high sensitivity and strong cytotoxic activity to human prostate cancer cell PC-3.The reaction condition of the application is relatively conventional, the reaction process is mild, simple, low in cost, suitable for industrial large-scale production, and the application range of the method is widened.

The invention relates to an aporphine-benzylisoquinoline alkaloid dimer as well as a preparation method and application thereof, and belongs to the field of natural medicines and biological medicines. The aporphine-benzylisoquinoline alkaloid dimer has a structural general formula shown in the specification, in the formula, R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, methoxyl, hydroxyl or two adjacent substituent groups are methylenedioxy, so that a five-membered ring is formed; and R9 is selected from hydrogen, methoxyl or hydroxyl. Six novel aporphine-benzylisoquinoline alkaloid dimers are extracted and separated from roots of thalictrum omeiensis, and through detection, the aporphine-benzylisoquinoline alkaloid dimers have obvious growth inhibition effects on human acute promyelocytic leukemia cells HL-60 and human prostate cancer cells PC-3, and have the prospect of preparing medicines for preventing and treating tumors.

The invention relates to a preparation method and application of aporphine-protoberberine alkaloid dimers, and belongs to the field of natural medicines and biological medicines. The aporphine-protoberberine alkaloid dimer disclosed by the invention has a structural general formula shown in the specification, in the formula, R1, R2, R3, R5, R6, R7, R8 and R9 are independently selected from hydrogen, methoxyl, hydroxyl or two adjacent substituent groups are methylenedioxy, so that a five-membered ring is formed; r4 is selected from hydrogen, methoxyl or hydroxyl. Six novel aporphine-protoberberine alkaloid dimers are extracted and separated from thalictrum omeiensis roots, and tests show that the aporphine-protoberberine alkaloid dimers have obvious growth inhibition effects on human acute promyelocytic leukemia cells HL-60 and human prostate cancer cells PC-3, can cause HL-60 cell cycle arrest in an S phase, induce HL-60 cell apoptosis, and can be used for preparing the aporphine-protoberberine alkaloid dimers. The compound has a prospect of preparing medicines for preventing and treating tumors.

A surgical training model for simulating human prostate surgery may include a harvested porcine urethra. A harvested porcine vagina surrounds a portion of the harvested porcine urethra to define a simulated human prostate.

The invention discloses a composition for treating prostatic cancer and application thereof. The composition is prepared from naringenin and cis-platinum. The application is the application of the composition for treating the prostatic cancer in preparation of drugs for treating the prostatic cancer. When the naringenin is combined with the cis-platinum, the inhibition effect on human prostate cancer cells DU-145 is obviously enhanced, a synergistic effect is achieved, and the naringenin and the cis-platinum have very small toxicity on normal HL-7702 cells. The naringenin combined with clinical drugs shows excellent in-vivo and in-vitro anti-tumor activity on human prostate cancer cells, has potential medicinal value and is expected to be used for preparing various anti-tumor drugs.

The application discloses a pentacyclic triterpene derivative shown in a general formula I or a pharmaceutically acceptable salt thereof, and further discloses a method for preparing the pentacyclic triterpene derivative by a chemical enzyme method, and application of the pentacyclic triterpene derivative or the pharmaceutically acceptable salt thereof in preparation of a drug for treating and preventing tumors. The hydroxyl group is used to further derive the B ring and / or the D ring of glycyrrhetinic acid for the first time; the novel pentacyclic triterpene molecule containing multiple Michael reaction acceptor modules in the structure is synthesized by taking the synthetic electrophilic warhead as the basis for the derivation of glycyrrhetinic acid; and through cell toxicity screening of the novel compound in the application, a drug lead compound with good inhibitory effect on human prostate cancer cells PC-3, human breast cancer cells MCF-7, human colon cancer cells SW480 and human cervical cancer cells Hela is found.

The present application relates to the field of natural products, in particular to a sesquiterpene and uric acid dimer compound of guaiane type and an extraction and separation method and application thereof. A new sesquiterpene and uric acid dimer compound of guaiane type is extracted and separated from Guizhoutianmingjing, and it is found that the compound has strong antitumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharyngeal carcinoma, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an alternative for broad-spectrum anticancer drugs. Moreover, in the paclitaxel-resistant human prostate cancer cell PC3, human cervical cancer cell Hela, human hepatoma cell HepG2 and human glioma cell U87, the compound also exhibits strong anticancer activity, indicating that it has the potential to treat paclitaxel-resistant patients.

The present invention relates to a lentiviral vector comprising a nucleic acid sequence encoding at least one antigen sequence selected from the group consisting of human prostatic acid phosphatase, human prostate specific antigen, human prostate-specific membrane antigen, human prostate stem cell antigen, human six-transmembrane epithelial antigen of the prostate-1 and fragments thereof. It further relates to lentiviral vector particles, isolated cells or pharmaceutical compositions comprising a lentiviral vector according to the invention. The invention further provides a combinatory treatment comprising at least one lentiviral vector, lentiviral vector particle, isolated cell or pharmaceutical composition according to the invention, and at least one anticancer agent or treatment and / or at least one immunotherapy agent or treatment. Finally, the invention provides any of the above for use in the treatment and / or prevention of prostate cancers, in particular of metastatic prostate cancers, more particularly of metastatic castration-resistant prostate cancers.

This invention relates to the fields of tumor biology and cell engineering, specifically disclosing the construction and application of a human prostate cancer cell line. The human prostate cancer cell line is derived from primary prostate cancer tissue, expresses prostate-specific antigen and α-methylacyl-CoA racemic enzyme, and has a 46,XY karyotype. The construction method employs an innovative strategy of co-culturing fully digested cell suspensions with incompletely digested tissue blocks, significantly improving the success rate of establishing the cell line from the primary lesion. This cell line can stably proliferate in conventional culture media supplemented with testosterone and has been successfully applied to subcutaneous tumorigenesis models in immunodeficient mice and in vivo migration models in zebrafish. The primary lesion-derived prostate cancer cell line provided by this invention offers a highly relevant, stable, and reliable new experimental tool for studying the biological characteristics of primary prostate cancer, drug screening, and personalized treatment.

The application discloses an indole and medium ring lactam compound and a synthesis method thereof, and a chemical structural formula of the indole and medium ring lactam compound is shown as formula 3; the synthesis method comprises the following steps: adding a compound 2-indole acetate of formula 1 and an o-chloromethyl aniline compound of formula 2 as reaction raw materials into an organic solvent, adding a base, stirring and reacting under a temperature condition of 0-40 DEG C, tracking the reaction to completion through TLC, and filtering, concentrating and purifying to obtain the indole and medium ring lactam compound. The indole and medium ring lactam compound synthesized by the application has high sensitivity and strong cytotoxicity to human prostate cancer cell PC-3 through a biological activity test. The reaction condition is very conventional, the reaction is carried out near room temperature, no metal is needed, and the operation is simple; the method can be used for large-scale amplification reaction of a gram level, and proves the potential of practical application; a plurality of kinds of substrates are used as reactants in the application, the indole and medium ring lactam compound with diversified structure is efficiently constructed, and the yield is high.

The present invention relates to treatment methods for prostate cancer using a combination of an anti-androgen compound and a T-cell engaging molecule that specifically binds to human prostate-specific membrane antigen (PSMA) and human CD3. In particular, the present invention relates to methods for treating prostate cancer, including metastatic castration-resistant prostate cancer, in a patient in need thereof comprising administering to the patient one or more cycles of an anti-androgen compound in combination with a PSMA-targeted T-cell engaging molecule, wherein administration of the first dose of the anti-androgen compound is delayed relative to administration of the first therapeutic dose of the PSMA-targeted T-cell engaging molecule in the first cycle.